July 13, 2026
SEOUL, South Korea, July 13, 2026 -
Elisigen, a clinical-stage biotechnology company developing AAV gene therapies
for ophthalmology and neurology, today announced a podium presentation at the
44th Annual Scientific Meeting of the American Society of Retina Specialists
(ASRS) being held in Montreal, Canada, from July 15 - 18, 2026. The
presentation will feature 44-week interim results from the medium-dose cohort
(Cohort 2) of the Phase 1/2a clinical trial evaluating NG101, an
investigational subretinal AAV gene therapy for wet age-related macular
degeneration (wet AMD).
ASRS 2026 Presentation Details:
Title: One-Year
First-in-Human Safety and Efficacy Data of Subretinal NG101 - A Novel Low-Dose
AAV Gene Therapy for Wet AMD: A Phase 1/2a Clinical Trial
Date/Time:
Thursday, July 16, 2026 (8:15 a.m. EDT)
Presenter: Peter
J. Kertes, MD, FRCS(C), Professor and Chair Department of Ophthalmology and
Vision Sciences, The University of Toronto
Session:
AMD-Neovascular Panel. Beyond anti-VEGF: Emerging Durable Therapies in
Neovascular AMD.
This presentation session showcases the
latest clinical results of next-generation therapies that go beyond
conventional anti-VEGF treatment, featuring a pipeline of high-dose protein
therapeutic, bispecific antibody, sustained-release implant, and AAV gene
therapies.
|
# |
Title |
Speaker |
|
1 |
Efficacy and safety of aflibercept 8 mg
in previously treated patients with nAMD or DME: 24-week results from the
phase 3b ELARA trial |
Eric Schneider, MD |
|
2 |
Results of a Randomized, Proof-of-Concept
Clinical Trial Comparing OLN324 with Faricimab in Patients with Neovascular
Age-Related Macular Degeneration |
David Eichenbaum, MD, FASRS |
|
3 |
Intravitreal Axitinib Hydrogel (OTX-TKI)
in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results
from the Phase 3 SOL-1 Trial |
Dilsher Dhoot, MD |
|
4 |
One-year, First-in-Human, Safety and
Efficacy Data for Subretinal NG101 – a Novel Low-dose AAV Gene Therapy for
Wet AMD: A Phase 1/2a Clinical Trial |
Peter Kertes, MD, FRCS(C) |
|
5 |
Ixoberogene soroparvovec (Ixo-vec)
intravitreal gene therapy for neovascular age-related macular degeneration
(nAMD): LUNA trial 2-year results |
Shawn Kavoussi, MD |
About NG101
NG101 is an investigational subretinal AAV
gene therapy for wet AMD. It is designed to provide sustained anti-VEGF
expression under Elisigen’s proprietary CAT311 promoter, with the goal of
durable disease control from a single administration at a substantially lower
vector dose. A Phase 1/2a open-label study is ongoing in the United States and
Canada. The U.S. Food and Drug Administration has granted Fast Track
designation for NG101 for the treatment of wet AMD.
About Elisigen
Elisigen is a clinical-stage biotechnology
company developing AAV gene therapies for ophthalmology and neurology.
Proprietary platforms include the CAT311 promoter for high-efficiency transgene
expression and the Helper-In-One (dual-plasmid) system for high-yield AAV
vector production. The company is headquartered in Seoul, Korea.
Contacts:
IR@elisigen.com